VRSN
59
4
MA
60
5
NKE
36
2
WFC
58
8
MET
58
2
BK
60
2
NSC
33
6
MMC
46
5
ZION
49
9
PFE
37
4
PNC
48
6
NTAP
58
3
ABBV
40
5
UAL
73
3
MS
64
3
PX
56
3
EMC
30
-26
AMAT
33
3
COP
36
2
AON
25
4
VRSN
59
4
MA
60
5
NKE
36
2
WFC
58
8
MET
58
2
BK
60
2
NSC
33
6
MMC
46
5
ZION
49
9
PFE
37
4
PNC
48
6
NTAP
58
3
ABBV
40
5
UAL
73
3
MS
64
3
PX
56
3
EMC
30
-26
AMAT
33
3
COP
36
2
AON
25
4
Financhill
Back

EyePoint Pharmaceuticals 10K Form

Sell
33

EYPT
EyePoint Pharmaceuticals

Last Price:
$7.12
Seasonality Move:
7.64%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EYPT News And Ratings

See the #1 stock for the next 7 days that we like better than EYPT

EYPT Financial Statistics

Sales & Book Value

Annual Sales: $46M
Cash Flow: $-40.6M
Price / Cash Flow: 0
Annual Sales: $4.09
Price / Book: 2.22

Profitability

EPS (TTM): -1.99000
Net Income (TTM): $-103.6M
Gross Margin: $41.4M
Return on Equity: -50.67%
Return on Assets: -35.24%

EyePoint Pharmaceuticals Earnings Forecast

Key EyePoint Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 16 years for EYPT is 89.93%.
  • The Selling, General & Administrative Expenses for EYPT have been equal to 112.55% of Gross Profit Margin.
  • The Research & Development expenses have been 140.51% of Revenue.
  • The Interest Expense is -1.76% of Operating Income.
  • The Net Earning history of EYPT is -153.84% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 10 years.

EyePoint Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: EYPT
CUSIP: 30233G
Website: eyepointpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.5
Quick Ratio: 5.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EYPT Technical Analysis vs Fundamental Analysis

Sell
33
EyePoint Pharmaceuticals (EYPT) is a Sell

Is EyePoint Pharmaceuticals a Buy or a Sell?